These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1737 related articles for article (PubMed ID: 22727733)

  • 1. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
    Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
    J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.
    Cheng AL; Guan Z; Chen Z; Tsao CJ; Qin S; Kim JS; Yang TS; Tak WY; Pan H; Yu S; Xu J; Fang F; Zou J; Lentini G; Voliotis D; Kang YK
    Eur J Cancer; 2012 Jul; 48(10):1452-65. PubMed ID: 22240282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
    World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
    Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
    Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
    Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
    Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
    Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
    Johnson PJ; Qin S; Park JW; Poon RT; Raoul JL; Philip PA; Hsu CH; Hu TH; Heo J; Xu J; Lu L; Chao Y; Boucher E; Han KH; Paik SW; Robles-Aviña J; Kudo M; Yan L; Sobhonslidsuk A; Komov D; Decaens T; Tak WY; Jeng LB; Liu D; Ezzeddine R; Walters I; Cheng AL
    J Clin Oncol; 2013 Oct; 31(28):3517-24. PubMed ID: 23980084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
    Kaneko S; Ikeda K; Matsuzaki Y; Furuse J; Minami H; Okayama Y; Sunaya T; Ito Y; Inuyama L; Okita K
    J Gastroenterol; 2016 Oct; 51(10):1011-21. PubMed ID: 26931117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
    Zhou L; Li J; Ai DL; Fu JL; Peng XM; Zhang LZ; Wang JY; Zhao Y; Yang B; Yu Q; Liu CZ; Wang HM
    Jpn J Clin Oncol; 2014 Aug; 44(8):711-7. PubMed ID: 24855686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the sorafenib patients assistance program on treatment compliance and overall survival of unresectable hepatocellular carcinoma patients.
    Lesmana LA; Gani RA; Hasan I; Waspodo A; Boedi P; Luwia MS; Ganggaiswari A
    Acta Med Indones; 2012 Jul; 44(3):228-32. PubMed ID: 22983078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
    Li J; Wang L; Cong N; Shi C; Bu W; Song J; Chen H
    Hepatogastroenterology; 2014 Jun; 61(132):954-7. PubMed ID: 26158148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma.
    Santini D; Addeo R; Vincenzi B; Calvieri A; Montella L; Silletta M; Caraglia M; Vespasiani U; Picardi A; Del Prete S; Tonini G
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1283-8. PubMed ID: 23094801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical course of sorafenib treatment in patients with hepatocellular carcinoma.
    Woo HY; Heo J; Yoon KT; Kim GH; Kang DH; Song GA; Cho M
    Scand J Gastroenterol; 2012 Jul; 47(7):809-19. PubMed ID: 22563643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
    Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
    Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
    Estfan B; Byrne M; Kim R
    Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
    Llovet JM; Decaens T; Raoul JL; Boucher E; Kudo M; Chang C; Kang YK; Assenat E; Lim HY; Boige V; Mathurin P; Fartoux L; Lin DY; Bruix J; Poon RT; Sherman M; Blanc JF; Finn RS; Tak WY; Chao Y; Ezzeddine R; Liu D; Walters I; Park JW
    J Clin Oncol; 2013 Oct; 31(28):3509-16. PubMed ID: 23980090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 87.